Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 6;2(2):CD013561.
doi: 10.1002/14651858.CD013561.pub2.

Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults

Lisa Caulley  1   2   3   4 , Jason G Quinn  5 , Mary-Anne Doyle  2   6 , Fahad Alkherayf  2   7 , Maria-Inti Metzendorf  8 , Shaun Kilty  1   2 , M G Myriam Hunink  9   10
Affiliations
Review

Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults

Lisa Caulley et al. Cochrane Database Syst Rev. .

Abstract

Background: Growth hormone (GH)-secreting pituitary adenoma is a severe endocrine disease. Surgery is the currently recommended primary therapy for patients with GH-secreting tumours. However, non-surgical therapy (pharmacological therapy and radiation therapy) may be performed as primary therapy or may improve surgical outcomes.

Objectives: To assess the effects of surgical and non-surgical interventions for primary and salvage treatment of GH-secreting pituitary adenomas in adults.

Search methods: We searched CENTRAL, MEDLINE, WHO ICTRP, and ClinicalTrials.gov. The date of the last search of all databases was 1 August 2022. We did not apply any language restrictions.

Selection criteria: Randomised controlled trials (RCTs) and quasi-RCTs of more than 12 weeks' duration, reporting on surgical, pharmacological, radiation, and combination interventions for GH-secreting pituitary adenomas in any healthcare setting.

Data collection and analysis: Two review authors independently screened titles and abstracts for relevance, screened for inclusion, completed data extraction, and performed a risk of bias assessment. We assessed studies for overall certainty of the evidence using GRADE. We estimated treatment effects using random-effects meta-analysis. We expressed results as risk ratios (RR) for dichotomous outcomes together with 95% confidence intervals (CI) or mean differences (MD) for continuous outcomes, or in descriptive format when meta-analysis was not possible.

Main results: We included eight RCTs that evaluated 445 adults with GH-secreting pituitary adenomas. Four studies reported that they included participants with macroadenomas, one study included a small number of participants with microadenomas. The remaining studies did not specify tumour subtypes. Studies evaluated surgical therapy alone, pharmacological therapy alone, or combination surgical and pharmacological therapy. Methodological quality varied, with many studies providing insufficient information to compare treatment strategies or accurately judge the risk of bias. We identified two main comparisons, surgery alone versus pharmacological therapy alone, and surgery alone versus pharmacological therapy and surgery combined. Surgical therapy alone versus pharmacological therapy alone Three studies with a total of 164 randomised participants investigated this comparison. Only one study narratively described hyperglycaemia as a disease-related complication. All three studies reported adverse events, yet only one study reported numbers separately for the intervention arms; none of the 11 participants were observed to develop gallbladder stones or sludge on ultrasonography following surgery, while five of 11 participants experienced any biliary problems following pharmacological therapy (RR 0.09, 95% CI 0.01 to 1.47; 1 study, 22 participants; very low-certainty evidence). Health-related quality of life was reported to improve similarly in both intervention arms during follow-up. Surgery alone compared to pharmacological therapy alone may slightly increase the biochemical remission rate from 12 weeks to one year after intervention, but the evidence is very uncertain; 36/78 participants in the surgery-alone group versus 15/66 in the pharmacological therapy group showed biochemical remission. The need for additional surgery or non-surgical therapy for recurrent or persistent disease was described for single study arms only. Surgical therapy alone versus preoperative pharmacological therapy and surgery Five studies with a total of 281 randomised participants provided data for this comparison. Preoperative pharmacological therapy and surgery may have little to no effect on the disease-related complication of a difficult intubation (requiring postponement of surgery) compared to surgery alone, but the evidence is very uncertain (RR 2.00, 95% CI 0.19 to 21.34; 1 study, 98 participants; very low-certainty evidence). Surgery alone may have little to no effect on (transient and persistent) adverse events when compared to preoperative pharmacological therapy and surgery, but again, the evidence is very uncertain (RR 1.23, 95% CI 0.75 to 2.03; 5 studies, 267 participants; very low-certainty evidence). Concerning biochemical remission, surgery alone compared to preoperative pharmacological therapy and surgery may not increase remission rates up until 16 weeks after surgery; 23 of 134 participants in the surgery-alone group versus 51 of 133 in the preoperative pharmacological therapy and surgery group showed biochemical remission. Furthermore, the very low-certainty evidence did not suggest benefit or detriment of preoperative pharmacological therapy and surgery compared to surgery alone for the outcomes 'requiring additional surgery' (RR 0.48, 95% CI 0.05 to 5.06; 1 study, 61 participants; very low-certainty evidence) or 'non-surgical therapy for recurrent or persistent disease' (RR 1.22, 95% CI 0.65 to 2.28; 2 studies, 100 participants; very low-certainty evidence). None of the included studies measured health-related quality of life. None of the eight included studies measured disease recurrence or socioeconomic effects. While three of the eight studies reported no deaths to have occurred, one study mentioned that overall, two participants had died within five years of the start of the study.

Authors' conclusions: Within the context of GH-secreting pituitary adenomas, patient-relevant outcomes, such as disease-related complications, adverse events and disease recurrence were not, or only sparsely, reported. When reported, we found that surgery may have little or no effect on the outcomes compared to the comparator treatment. The current evidence is limited by the small number of included studies, as well as the unclear risk of bias in most studies. The high uncertainty of evidence significantly limits the applicability of our findings to clinical practice. Detailed reporting on the burden of recurrent disease is an important knowledge gap to be evaluated in future research studies. It is also crucial that future studies in this area are designed to report on outcomes by tumour subtype (that is, macroadenomas versus microadenomas) so that future subgroup analyses can be conducted. More rigorous and larger studies, powered to address these research questions, are required to assess the merits of neoadjuvant pharmacological therapy or first-line pharmacotherapy.

PubMed Disclaimer

Conflict of interest statement

Lisa Caulley (LC): was supported by the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award and the PSI Foundation Research Trainee Award. Jason G Quinn (JQ): none known Mary‐Anne Doyle (MD): none known Fahad Alkherayf (FA): none known Maria‐Inti Metzendorf (MIM): is part of the Cochrane Metabolic and Endocrine Disorders team, however, she has not been involved in the editorial processing of this manuscript. Shaun Kilty (SK): none known MG Myriam Hunink (MG): receives royalties from Cambridge University Press for a textbook on decision‐making and received reimbursement for travel and lodging from the European Society of Radiology and the European Institute for Biomedical Imaging Research.

Update of

  • doi: 10.1002/14651858.CD013561

Similar articles

See all similar articles

References

References to studies included in this review

Cannavo 2001 {published data only}
    1. Cannavo S, Squadrito S, Curto L, Almoto B, Trimarchi F. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Hormone and Metabolic Research 2001;8(10):618-24. - PubMed
Colao 2009 {published data only}
    1. Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clinical Endocrinology 2009;70(5):757-68. - PubMed
Fahlbusch 2017 {published data only}
    1. Fahlbusch R, Kleinberg D, Biller B, Bonert V, Buchfelder M, Cappabianca P, et al. Surgical debulking of pituitary adenomas improves responsiveness to octreotide LAR in the treatment of acromegaly. Pituitary 2017;20(6):668-75. - PubMed
Fougner 2014 {published and unpublished data}
    1. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism 2008;93(8):2984-90. - PubMed
    1. Fougner SL, Bollerslev J, Svartberg J, Øksnes M, Cooper J, Carlsen SM. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. European Journal of Endocrinology 2014;171(2):229-35. - PubMed
    1. Helseth R, Carlsen SM, Bollerslev J, Svartberg J, Øksnes M, Skeie S, et al. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 2016;51(2):298-307. - PubMed
Karaca 2011 {published data only}
    1. Karaca Z, Tanriverdi F, Elbuken G, Cakir I, Donmez H, Selcuklu A, et al. Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly. Clinical Endocrinology 2011;75(5):678-84. - PubMed
Li 2012 {published data only}
    1. Li ZQ, Quan Z, Tian HL, Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. Journal of International Medical Research 2012;40(2):517-24. - PubMed
Mao 2010 {published data only}
    1. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. European Journal of Endocrinology 2010;162(4):661-6. - PubMed
Shen 2010 {published data only}
    1. Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocrine Journal 2010;57(12):1035-44. - PubMed

References to studies excluded from this review

Amato 2002 {published data only}
    1. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology 2002;56(1):65-71. - PubMed
Andries 2008 {published data only}
    1. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clinical Endocrinology 2008;68(3):473-80. - PubMed
Bronstein 2016 {published data only}
    1. Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocrine Disorders 2016;16:16. - PMC - PubMed
Chieffo 2013 {published data only}
    1. Chieffo C, Cook D, Xiang Q, Frohman LA. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2013;98(10):4047-54. - PubMed
Colao 1997 {published data only}
    1. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1997;82(2):518-23. - PubMed
Colao 2014 {published and unpublished data}
    1. Colao A, Bronstein MD, Brue T, Coculescu MG, Fleseriu M, Guitelman M, et al. Phase III, multicenter, randomized study (PAOLA) demonstrating that pasireotide LAR has superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly. Endocrine Reviews 2014;35:no pagination.
    1. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism 2014;99(3):791-9. - PMC - PubMed
Colao 2019 {published data only}
    1. Colao A, Zgliczynski W, Komorowski J, Kos-Kudla B, Tabarin A, Kerlan V, et al. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynologia Polska 2019;70(4):305-12. - PubMed
Cozzi 1999 {published data only}
    1. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. European Journal of Endocrinology 1999;141(3):267-71. - PubMed
Ferone 2017 {published data only}
    1. Ferone D, Borson-Chazot F, Cailleux A, Horsch D, Lahner H, Pivonello R, et al. The novel, ready-to-use octreotide subcutaneous (SC) depot provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumors (NETs) previously treated with long-acting octreotide: results from a phase 2, open-label, multicenter, randomized study. Endocrine Reviews 2017;38(3).
Ferrari 1983 {published data only}
    1. Ferrari C, Romussi M, Benco R, Rampini P, Mailland F. Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions. Acta Endocrinologica (Copenhagen) 1983;103(1):1-6. - PubMed
Fleseriu 2014 {published data only}
    1. Fleseriu M, Gadelha M, Bronstein MD, Brue T, Coculescu M, Guitelman M, et al. Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multicenter, randomized study (PAOLA). Growth Hormone & IGF Research 2014;24:S20-S21.
Fleseriu 2016 {published data only}
    1. Fleseriu M, Popovic V, Biermasz NR, Ludlam WH, Grossman AB. Novel approach to dose optimization of oral octreotide in patients with acromegaly transitioned from injectable somatostatin analogs. Endocrine Reviews 2016;37:no pagination.
Fløgstad 1995 {published data only}
    1. Fløgstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, et al. Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism 1995;80(12):3601-7. - PubMed
Fredstorp 1990 {published data only}
    1. Fredstorp L, Harris A, Haas G, Werner S. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects. Journal of Clinical Endocrinology and Metabolism 1990;71(5):1189-94. - PubMed
Gadelha 2012 {published data only}
    1. Gadelha MR, Chieffo C, Bai SA, Hu X, Frohman LA. A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. Endocrine Practice 2012;18(6):870-81. - PubMed
Gadelha 2014 {published data only}
    1. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes & Endocrinology 2014;2(11):875-84. - PubMed
Gadelha 2015 {published data only}
    1. Gadelha MR, Bronstein MD, Brue T, Gr Coculescu M, De Marinis L, Fleseriu M, et al. Biochemical control is maintained with pasireotide LAR in patients with acromegaly: results from the extension of a randomized phase III study (PAOLA). Endocrine Reviews 2015;36:no pagination.
Gadelha 2017 {published data only}
    1. Gadelha MR, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, et al. Long-acting pasireotide provides clinical benefit in patients with acromegaly: results from a 30-month analysis of the phase 3 PAOLA study. Endocrine Reviews 2017;38(3):no pagination.
Gadelha 2019 {published data only}
    1. Gadelha M, Bex M, Colao A, Pedroza Garcia EM, Poiana C, Jimenez-Sanchez M, et al. Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Frontiers in Endocrinology 2019;10:931. - PMC - PubMed
Ghigo 2009 {published data only}
    1. Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. Journal of Endocrinological Investigation 2009;32(11):924-33. - PubMed
Giustina 2009 {published data only}
    1. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European Journal of Endocrinology 2009;161(2):331-8. - PubMed
    1. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, et al. High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial. Endocrine Abstracts 2010;20:OC4.1‐.
Giustina 2010 {published data only}
    1. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, et al. High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial. Endocrine Abstracts 2010;20.
Giustina 2017 {published data only}
    1. Giustina A, Mazziotti G, Cannavo S, Castello R, Arnaldi G, Bugari G, et al. High-dose and high-frequency lanreotide autogel in acromegaly patients inadequately controlled on conventional somatostatin analog therapy: a randomized, open label, multicenter study. Endocrine Reviews 2017;38(3):2454-64.
    1. Giustina A, Mazziotti G, Cannavo S, Castello R, Arnaldi G, Bugari G, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. Journal of Clinical Endocrinology and Metabolism 2017;102(7):2454-64. - PubMed
Halse 1990 {published data only}
    1. Halse J, Harris AG, Kvistborg A, Kjartansson O, Hanssen E, Smiseth O, et al. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. Journal of Clinical Endocrinology and Metabolism 1990;70(5):1254-61. - PubMed
Herman‐Bonert 2000 {published data only}
    1. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 2000;85(8):2958-2961//RTY - Journal article. - PubMed
Imani 2018 {published data only}
    1. Imani M, Khamseh ME, Asadi P, Ghorbani M, Akbari H, Alaei-Shahmiri F, et al. Comparison of cabergoline versus raloxifene add-on therapy to long-acting somatostatin analogue in patients with inadequately controlled acromegaly: a randomized open label clinical trial. Endocrine Practice 2018;24(6):542-47. - PubMed
Jain 2007 {published data only}
    1. Jain AK, Gupta AK, Pathak A, Bhansali A, Bapuraj JR. Excision of pituitary adenomas: randomized comparison of surgical modalities. British Journal of Neurosurgery 2007;21(4):328-31. - PubMed
Jaquet 1997 {published data only}
    1. Jaquet P. Evidence for dopamine agonists in the treatment of acromegaly. Journal of Endocrinology 1997;155 Suppl 1:S59-60. - PubMed
Jenkins 2000 {published data only}
    1. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology 2000;53(6):719-24. - PubMed
Kristof 1999 {published data only}
    1. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochirurgica 1999;141(4):399-405. - PubMed
Lancranjan 1996 {published data only}
    1. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism: Clinical and Experimental 1996;45(8 Suppl 1):67-71. - PubMed
Lindholm 1981 {published data only}
    1. Lindholm J, Riishede J, Vestergaard S, Hummer L, Faber O, Hagen C. No effect of bromocriptine in acromegaly: a controlled trial. New England Journal of Medicine 1981;304(24):1450-4. - PubMed
Ma 2005 {published data only}
    1. Ma P, Wang Y, Van der Hoek J, Nedelman J, Schran H, Tran LL, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clinical Pharmacology and Therapeutics 2005;78(1):69-80. - PubMed
Madsen 2011 {published data only}
    1. Madsen M, Poulsen PL, Orskov H, Møller N, Jørgensen JO. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2011;96(8):2405-13. - PubMed
Mazziotti 2011 {published data only}
    1. Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavo S, Colao A, et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. European Journal of Endocrinology 2011;164(3):341-7. - PubMed
Melmed 2010 {published data only}
    1. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13(1):18-28. - PMC - PubMed
Neggers 2008 {published data only}
    1. Neggers SJ, Van Aken MO, De Herder WW, Feelders RA, Janssen JA, Badia X, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008;93(10):3853-9. - PubMed
Newman 1998 {published data only}
    1. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998;83(9):3034-40. - PubMed
Oppizzi 1984 {published data only}
    1. Oppizzi G, Liuzzi A, Chiodini P, Dallabonzana D, Spelta B, Silvestrini F, et al. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. Journal of Clinical Endocrinology and Metabolism 1984;58(6):988-92. - PubMed
Pavel 2019 {published data only}
    1. Pavel M, Borson-Chazot F, Cailleux A, Horsch D, Lahner H, Pivonello R, et al. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemotherapy and Pharmacology 2019;83(2):375-85. - PubMed
Petersenn 2010 {published data only}
    1. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 2010;95(6):2781-9. - PubMed
Petersenn 2014 {published data only}
    1. Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, et al. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. Journal of Clinical Pharmacology 2014;54(11):1308-17. - PubMed
Schmid 2014 {published data only}
    1. Schmid HA, Brue T, Colao A, Gadelha M, Shimon I, Kapur K, et al. Exploratory data evaluating the effect of pasireotide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and glucose in patients with inadequately controlled acromegaly enrolled in a 24-week study (PAOLA). Endocrine Reviews 2014;35:no pagination.
Schmid 2016 {published data only}
    1. Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 2016;53(1):210-9. - PMC - PubMed
Sesmilo 2002 {published data only}
    1. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. Journal of Clinical Endocrinology and Metabolism 2002;87(4):1692-9. - PubMed
Sheppard 2015 {published data only}
    1. Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary 2015;18(3):385-94. - PMC - PubMed
Stevenaert 1993 {published data only}
    1. Stevenaert A, Harris AG, Kovacs K, Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism, Clinical and Experimental 1992;41(9):51-8. - PubMed
Tahara 2017 {published data only}
    1. Tahara S, Murakami M, Kaneko T, Shimatsu A. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocrine Journal 2017;64(7):735-47. - PubMed
Trainer 2000 {published data only}
    1. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000;342(16):1171-7. - PubMed
Trainer 2009 {published data only}
    1. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clinical Endocrinology 2009;71(4):549-57. - PubMed
Trainer 2018 {published data only}
    1. Trainer PJ, Newell-Price JD, Ayuk J, Aylwin SJ, Rees A, Drake W, et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology 2018;179(2):97-108. - PMC - PubMed
Tutuncu 2012 {published data only}
    1. Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 2012;15(3):398-404. - PMC - PubMed
Van der Hoek 2005 {published data only}
    1. Van der Hoek J, Van der Lelij AJ, Feelders RA, De Herder WW, Uitterlinden P, Poon KW, et al. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clinical Endocrinology 2005;63(2):176-84. - PubMed
Wang 2018 {published data only}
    1. Wang X, Zhang Y, Xiao J, Zhang K, Li Q, Chen H, et al. 18 beta-glycyrrhetinic acid ameliorates the cognitive functions and decreases the recurrence rate of pituitary adenomas patients. EXCLI Journal 2018;17:753-61. - PMC - PubMed
Weeke 1992 {published data only}
    1. Weeke J, Christensen SE, Orskov H, Kaal A, Pedersen MM, Illum P, et al. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1992;75(1):163-9. - PubMed

References to studies awaiting assessment

Thapar 1997 {published data only}
    1. Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1994;79:113-8. - PubMed
    1. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology 1995;133:686-90. - PubMed
    1. Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clinic Proceedings 1997;72(10):893-900. - PubMed

References to ongoing studies

ChiCTR2100048869 {published data only}
    1. ChiCTR2100048869. Prospective randomized controlled trial of preoperative SSA treatment of invasive growth hormone pituitary adenoma. http://www.chictr.org.cn/showproj.aspx?proj=130559 (first received 19 July 2021).

Additional references

Abu Dabrh 2014
    1. Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, et al. Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism 2014;99(11):4003-14. - PMC - PubMed
Abu Dabrh 2015
    1. Abu Dabrh AM, Asi N, Farah WH, Mohammed K, Wang Z, Farah MH, et al. Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis. Endocrine Practice 2015;21(8):943-56. [DOI: 10.4158/EP14574.OR] - DOI - PubMed
Agustsson 2015
    1. Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. European Journal of Endocrinology 2015;173(5):655-64. - PubMed
Albarel 2022
    1. Albarel F, Cuny T, Graillon T, Dufour H, Brue T, Castinetti F. Medical Treatment for Patients With Acromegaly. Journal of the Endocrine Society 2022;6(9):bvac114. - PMC - PubMed
Altman 2003
    1. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. [PMID: ] - PMC - PubMed
Ammirati 2013
    1. Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. Journal Neurology, Neurosurgery, and Psychiatry 2013;84(8):843-9. - PMC - PubMed
Anik 2017
    1. Anik I, Cabuk B, Gokbel A, Selek A, Cetinarslan B, Anik Y, et al. Endoscopic transsphenoidal approach for acromegaly with remission rates in 401 patients: 2010 consensus criteria. World Neurosurgery 2017;108:278-90. - PubMed
Baldelli 2003
    1. Baldelli R, Battista C, Leonetti F, Ghiggi M, Ribaudo M, Paoloni A, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 2003;59(4):492-9. - PubMed
Ben‐Shlomo 2003
    1. Ben-Shlomo A, Melmed S. Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. Journal of Clinical Endocrinology Metabolism 2003;88(3):963-8. - PubMed
Ben‐Shlomo 2008
    1. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinology and Metabolism Clinics of North America 2008;37(1):101-22. - PMC - PubMed
Biering 2006
    1. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology 2006;154(2):213-20. - PubMed
Bonert 2008
    1. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. Journal of Clinical Endocrinology & Metabolism 2008;93(9):3515-8. - PubMed
Buchfelder 2014
    1. Buchfelder M, Schlaffer S. Imaging of pituitary pathology. Handbook of Clinical Neurology 2014;124:151-66. - PubMed
Cappellani 2018
    1. Cappellani D, Urbani C, Sardella C, Scattina I, Marconcini G, Lupi I, et al. Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinology, Diabetes and Metabolism 2018;2(1):e00033. - PMC - PubMed
Carmichael 2009
    1. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology & Metabolism 2009;94(2):523–7. [DOI: 10.1210/jc.2008-1371] - DOI - PubMed
Caron 2014
    1. Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. Journal of Clinical Endocrinology & Metabolism 2014;99(4):1282-90. - PMC - PubMed
Castinetti 2010
    1. Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nature Reviews Endocrinology 2010;6(4):214-23. - PubMed
Cavallo 2005
    1. Cavallo LM, Messina A, Gardner P, Esposito F, Kassam AB, Cappabianca P, et al. Extended endoscopic endonasal approach to the pterygopalatine fossa: anatomical study and clinical considerations. Neurosurgical Focus 2005;19(1):E5. - PubMed
Chanson 2009
    1. Chanson P, Bertherat J, Beckers A, Bihan H, Brue T, Caron P, et al. French consensus on the management of acromegaly. Annales d'Endocrinologie 2009;70(2):92-106. - PubMed
Chanson 2015
    1. Chanson P. Medical treatment of acromegaly with dopamine agonists or somatostatin analogs. Neuroendocrinology 2015;103(1):50-8. [DOI: 10.1159/000377704] - DOI - PubMed
Cochrane 2022
    1. Cochrane. CENTRAL creation details. www.cochranelibrary.com/central/central-creation (accessed 1 August 2022).
Colao 2004
    1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004;25(1):102-52. - PubMed
Colao 2008
    1. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. Journal of Clinical Endocrinology and Metabolism 2008;93(7):2639-46. - PubMed
CONSORT 2018
    1. Consolidated Standards of Reporting Trials (CONSORT). The CONSORT statement. www.consort-statement.org (accessed 6 January 2020).
Deeks 2022
    1. Deeks JJ, Higgins JP, Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Dekkers 2008
    1. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology & Metabolism 2008;93(1):61-7. - PubMed
Diallo 2015
    1. Diallo AM, Colin P, Litre CF, Diallo MM, Decoudier B, Bertoin F, et al. Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly. Endocrine 2015;50(3):741-8. - PubMed
Dworakowska 2010
    1. Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. European Journal of Endocrinology 2010;163(1):21-8. - PubMed
Fleseriu 2015
    1. Fleseriu M, Hoffman AR, Katznelson L, AACE Neuroendocrine and Pituitary Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: management of acromegaly patients: what is the role of pre-operative medical therapy? Endocrine Practice 2015;21(6):668-73. [DOI: 10.4158/EP14575.DSCR] - DOI - PubMed
Fleseriu 2021
    1. Fleseriu M, Biller BM, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021;24(1):1-13. - PMC - PubMed
Franck 2016
    1. Franck SE, Muhammad A, Van der Lely AJ, Neggers SJ. Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine 2016;52(2):206-13. [DOI: 10.1007/s12020-015-0810-8] - DOI - PMC - PubMed
GRADEproGDT [Computer program]
    1. GRADEpro GDT. Version accessed before December 2023. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Guistina 2014
    1. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology 2014;10:243-8. - PubMed
Heck 2016
    1. Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 2016;52(2):333-43. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Altman DG, Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins 2022a
    1. Higgins JP, Li T, Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Higgins 2022b
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Ho 1992
    1. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clinical Endocrinology 1992;36(3):271-9. - PubMed
Hoffmann 2014
    1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687. - PubMed
Hoffmann 2017
    1. Hoffmann TC, Oxman AD, Ioannidis JP, Moher D, Lasserson TJ, Tovey DI, et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ 2017;358:j2998. - PubMed
Holdaway 2008
    1. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 2008;159(2):89-95. - PubMed
Hoskuldsdottir 2015
    1. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary 2015;18(6):803-7. - PubMed
Hozo 2005
    1. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5:13. [DOI: 10.1186/1471-2288-5-13] - DOI - PMC - PubMed
Hussein 2019
    1. Hussein Z, Bidin ML, Alias A, Thiagarajan M, Latif KA, Ratnasingam J, et al. Malaysian consensus statement for the diagnosis and management of acromegaly. Journal of the ASEAN Federation of Endocrine Societies 2019;34(1):8. - PMC - PubMed
Jaffe 1992
    1. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinology and Metabolism Clinics of North America 1992;21(3):713-35. - PubMed
Jenkins 2006
    1. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. Journal of Clinical Endocrinology & Metabolism 2006;91(4):1239-45. - PubMed
Jho 1997
    1. Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. Journal of Neurosurgery 1997;87(1):44-51. - PubMed
Kassam 2005a
    1. Kassam AB, Carrau RL, Snyderman CH, Gardner P, Mintz A. Evolution of reconstructive techniques following endoscopic expanded endonasal approaches. Neurosurgical Focus 2005;19(1):E8. - PubMed
Kassam 2005b
    1. Kassam AB, Snyderman CH, Mintz A, Gardner P, Carrau RL. Expanded endonasal approach: the rostrocaudal axis. Part I. Crista galli to the sella turcica. Neurosurgical Focus 2005;19(1):E3. - PubMed
Kassam 2005c
    1. Kassam AB, Snyderman CH, Mintz A, Gardner P, Carrau RL. Expanded endonasal approach: the rostrocaudal axis. Part II. Posterior clinoids to the foramen magnum. Neurosurgical Focus 2005;19(1):E4. - PubMed
Kassam 2005d
    1. Kassam AB, Gardner P, Snyderman C, Mintz A, Carrau R. Expanded endonasal approach: fully endoscopic, completely transnasal approach to the middle third of the clivus, petrous bone, middle cranial fossa, and infratemporal fossa. Neurosurgical Focus 2005;19(1):E6. - PubMed
Kassam 2005e
    1. Kassam AB, Snyderman C, Gardner P, Carrau R, Spiro R. The expanded endonasal approach: a fully endoscopic transnasal approach and resection of the odontoid process: technical case report. Neurosurgery 2005;57(1 Suppl):E213. - PubMed
Katznelson 2011
    1. Katznelson L, Atkinson J, Cook D, Ezzat S, Hamrahian A, Miller K. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocrine Practice 2011;17 Suppl 4:1-44. [DOI: 10.4158/EP.17.S4.1] - DOI - PubMed
Katznelson 2014
    1. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2014;99(11):3933-51. [DOI: 10.1210/jc.2014-2700] - DOI - PubMed
Kirkham 2010
    1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365] - DOI - PubMed
Komotar 2012
    1. Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas. World Neurosurgery 2012;77(2):329-41. [DOI: 10.1016/j.wneu.2011.07.011] - DOI - PubMed
Kreutzer 2001
    1. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology & Metabolism 2001;86(9):4072-7. - PubMed
Lavrentaki 2016
    1. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary 2016;20(1):4-9. - PMC - PubMed
Lee 2014
    1. Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, et al. Stereotactic radiosurgery for acromegaly. Journal of Clinical Endocrinology & Metabolism 2014;99(4):1273-81. [DOI: 10.1210/jc.2013-3743] - DOI - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLOS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] - DOI - PMC - PubMed
Loeffler 2011
    1. Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. Journal of Clinical Endocrinology & Metabolism 2011;96(7):1992-2003. [DOI: 10.1210/jc.2011-0251] - DOI - PubMed
Marshall 2018
    1. Marshall IJ, Noel-Storr AH, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying randomized controlled trials: an evaluation and practitioner’s guide. Research Synthesis Methods 2018;9(4):602-14. - PMC - PubMed
McDonald 2017
    1. McDonald S, Noel-Storr AH, Thomas J. In: Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. Global Evidence Summit; 2017 Sept 13-16; Cape Town (South Africa). Cape Town (South Africa): Global Evidence Summit, 2017.
Melmed 2006
    1. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006;355(24):2558-73. [DOI: 10.1056/NEJMra062453] - DOI - PubMed
Melmed 2009a
    1. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009;119(11):3189-202. [DOI: 10.1172/JCI3937] - DOI - PMC - PubMed
Melmed 2009b
    1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology & Metabolism 2009;94(5):1509-17. [DOI: 10.1210/jc.2008-2421] - DOI - PubMed
Melmed 2016
    1. Melmed S, Kleinberg D. Pituitary masses and tumors. In: Melmed S, Polonsky KP, Larsen R, Kronenberg H, editors(s). Williams Textbook of Endocrinology. Philadelphia, PA: Elsevier, 2016. [9780323341578]
Melmed 2018
    1. Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JA, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology 2018;14(9):552-61. - PMC - PubMed
Mercado 2007
    1. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 2007;66(6):859-68. [DOI: 10.1111/j.1365-2265.2007.02825.x] - DOI - PMC - PubMed
Mercado 2014
    1. Mercado M, Gonzalez B, Vargas G, Ramirez C, los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. Journal of Clinical Endocrinology & Metabolism 2014;99(12):4438-46. [DOI: 10.1210/jc.2014-2670] - DOI - PubMed
Molitch 2017
    1. Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317(5):516-24. [DOI: 10.1001/jama.2016.19699] - DOI - PubMed
Nemergut 2005
    1. Nemergut EC, Dumont AS, Barry UT, Laws ER. Perioperative management of patients undergoing transsphenoidal pituitary surgery. Anesthesia & Analgesia 2005;101(4):1170-81. - PubMed
Noel‐Storr 2018
    1. Noel-Storr AH and the Project Transform team. In: Cochrane Crowd: new ways of working together to produce health evidence. Evidence Live 2018; 2018 Jun 18-20; Oxford (UK). Oxford (UK): Evidence Live, 2018.
Nunes 2015
    1. Nunes VS, Correa JM, Puga ME, Silva EM, Boguszewski CL. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary 2015;18(4):500-8. - PubMed
Phan 2017
    1. Phan K, Xu J, Reddy R, Kalakoti P, Nanda A, Fairhall J. Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis. World Neurosurgery 2017;97:398-406. [DOI: 10.1016/j.wneu.2016.10.029] - DOI - PubMed
Potorac 2015
    1. Potorac I, Petrossians P, Daly AF, Schillo F, Slama CB, Nagi S, et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer 2015;22(2):169-77. - PubMed
Potorac 2016
    1. Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer 2016;23(11):871-81. - PubMed
Puig‐Domingo 2010
    1. Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Journal of Clinical Endocrinology & Metabolism 2010;95(11):4973-8. - PubMed
Qiao 2021
    1. Qiao N, Shen M, He W, He M, Zhang Z, Ye H, et al. Comparative effectiveness of endoscopic versus microscopic transsphenoidal surgery for patients with growth hormone secreting pituitary adenoma: an emulated trial. Clinical Neurology and Neurosurgery 2021;207:106781-106781. - PubMed
Raverot 2018
    1. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology 2018;178(1):G1-24. - PubMed
Rokkas 2008
    1. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World Journal of Gastroenterology 2008;14(22):3484-9. - PMC - PubMed
Ronchi 2006
    1. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism 2005;91(1):121-8. - PubMed
Rosario 2011
    1. Rosario PW. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 2011;14(3):217-21. - PubMed
Sabino 2010
    1. Sabino SM, Miranda PA, Ribeiro-Oliveira A Jr. Growth hormone-secreting pituitary adenomas: from molecular basis to treatment options in acromegaly. Cancer Biology and Therapy 2010;9(7):483-92. - PubMed
Salvatori 2014
    1. Salvatori R, Woodmansee WW, Molitch M, Gordon MB, Lomax KG. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 2014;17(1):13-21. [DOI: 10.1007/s11102-012-0460-2] - DOI - PMC - PubMed
Sandret 2011
    1. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. Journal of Clinical Endocrinology & Metabolism 2011;96(5):1327-35. - PubMed
Scherer 2018
    1. Scherer RW, Meerpohl JJ, Pfeifer N, Schmucker C, Schwarzer G, Elm E. Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews 2018, Issue 11. Art. No: MR000005. [DOI: 10.1002/14651858.MR000005.pub4] - DOI - PMC - PubMed
Schmitt 2000
    1. Schmitt H, Buchfelder M, Radespiel-Troger M, Fahlbusch R. Difficult intubation in acromegalic patients: incidence and predictability. Anesthesiology 2000;93(1):110-4. - PubMed
Schöfl 2013
    1. Schöfl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. European Journal of Endocrinology 2013;168(1):39-47. - PubMed
Schünemann 2022
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Seidman 2000
    1. Seidman PA, Kofke WA, Policare R, Young M. Anaesthetic complications of acromegaly. British Journal of Anaesthesia 2000;84(2):179-82. - PubMed
Sesmilo 2017
    1. Sesmilo G, Resmini E, Sambo M, Blanco C, Calvo F, Pazos F, et al. Prevalence of acromegaly in patients with symptoms of sleep apnea. PLOS One 2017;12(9):e0183539. [DOI: 10.1371/journal.pone.0183539] - DOI - PMC - PubMed
Shen 2016
    1. Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z, et al. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 2016;58(11):1057-65. - PubMed
Sherlock 2009
    1. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, et al. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. Journal of Clinical Endocrinology & Metabolism 2009;94(4):1255-63. - PubMed
Shih 2008
    1. Shih HA, Loeffler JS. Radiation therapy in acromegaly. Reviews in Endocrine and Metabolic Disorders 2008;9(1):59-65. [DOI: 10.1007/s11154-007-9065-x] - DOI - PubMed
Sterne 2011
    1. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. - PubMed
Stevenaert 1996
    1. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996;45(8):72-4. - PubMed
Stewart 2000
    1. Stewart PM. Current therapy for acromegaly. Trends in Endocrinology and Metabolism 2000;11(4):128-32. [DOI: 10.1016/s1043-2760(00)00244-7] - DOI - PubMed
Swearingen 2012
    1. Swearingen B. Update on pituitary surgery. Journal of Clinical Endocrinology & Metabolism 2012;97(4):1073-81. [DOI: 10.1210/jc.2011-3237] - DOI - PubMed
Thomas 2017
    1. Thomas J, Noel-Storr AH, Marshall I, Wallace B, McDonald S, Mavergames C, et al. Living systematic reviews: 2. combining human and machine effort. Journal of Clinical Epidemiology 2017;S0895-4356(17):30604-2. - PubMed
Tortora 2019
    1. Tortora F, Negro A, Grasso LF, Colao A, Pivonello R, Splendiani A, et al. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. Gland Surgery 2019;8 Suppl 3:S150-8. [DOI: 10.21037/gs.2019.06.04] - DOI - PMC - PubMed
Turner 2000
    1. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JH. Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology & Metabolism 2000;85(3):1159-62. [DOI: 10.1210/jc.85.3.1159] - DOI - PubMed
Van der Lely 2001
    1. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-9. - PubMed
Van der Lely 2012
    1. Van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. Journal of Clinical Endocrinology & Metabolism 2012;97(5):1589–97. - PubMed
Vilar 2017
    1. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary 2017;20(1):22-32. [DOI: 10.1007/s11102-016-0772-8] - DOI - PubMed
Villwock 2014
    1. Villwock JA, Villwock M, Deshaies E, Goyal P. Significant increases of pituitary tumors and resections from 1993 to 2011. International Forum of Allergy and Rhinology 2014;4(9):767-70. [DOI: 10.1002/alr.21356] - DOI - PubMed
Wilson 1990
    1. Wilson CB. Role of surgery in the management of pituitary tumors. Neurosurgery Clinics of North America 1990;1(1):139-59. - PubMed
Wilson 2013
    1. Wilson TJ, McKean EL, Barkan AL, Chandler WF, Sullivan SE. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary 2013;16(4):459-64. [DOI: 10.1007/s11102-012-0457-x] - DOI - PubMed
Witte 2001
    1. Witte RJ, Mark LP, Daniels DL, Haughton VM. Radiographic evaluation of the pituitary and anterior hypothalamus. In: DeGroot LJ, JamesonJL, editors(s). Endocrinology. 4th edition. Philadelphia: WB Saunders, 2001:257-68.
Wolinksi 2014
    1. Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review. PLOS One 2014;9(2):e88787. [DOI: 10.1371/journal.pone.0088787] - DOI - PMC - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5. - PMC - PubMed
Yang 2019
    1. Yang C, Ge L, Jiang S, Bao X, Wang R. Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and metaanalysis of comparative studies. Scientific Reports 2019;9:14070. - PMC - PubMed
Zahr 2018
    1. Zahr R, Fleseriu M. Updates in diagnosis and treatment of acromegaly. European Endocrinology 2018;14(2):57-61. - PMC - PubMed
Zhang 2015
    1. Zhang L, Wu X, Yan Y, Qian J, Lu Y, Luo C. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis. Brain & Development 2015;37(2):181-90. - PubMed

References to other published versions of this review

Caulley 2020
    1. Caulley L, Quinn JG, Doyle M-A, Alkherayf F, Kilty S, Hunink MG. Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No: CD013561. [DOI: 10.1002/14651858.CD013561] - DOI - PMC - PubMed

LinkOut - more resources